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ABSTRACT 
Aims: Overall, 40% of patients with atrial fibrillation (AF) are asymptomatic. The 
usefulness and cost-effectiveness of AF screening programmes are debated. We 
evaluated if an AF screening programme with a handheld ECG machine in a 
population-wide cohort has a high screening yield and is cost-effective. 
Methods: We used a Markov-model based modelling analysis on 1000 hypothetical 
individuals that matched the Belgian Heart Rhythm Week Screening Programme. 
Subgroup analyses of subjects ≥65 and ≥75 years old were performed. Screening 
was performed with one-lead ECG handheld machine Omron® HeartScan HCG-801. 
Results: In both overall population and subgroups, the use of the screening 
procedure diagnosed a consistently higher number of diagnosed AF than not 
screening. In the base-case scenario, the screening procedure resulted in 106.6 
more AF patient-years, resulting in 3 fewer strokes, 10 more life-years and 5 more 
QALYs. The number needed-to-screen (NNS) to avoid 1 stroke was 361. In subjects 
≥65, we found 80.8 more AF patient-years resulting in 3 fewer strokes, 4 more life-
years and 5 more QALYs. The NNS to avoid 1 stroke was 354. Similar results were 
obtained in subjects ≥75 years, with a NNS to avoid one stroke of 371. In the overall 
population, the incremental cost-effectiveness ratio for any gained QALY showed 
that the screening procedure was cost-effective in all groups. 
Conclusions: In a population-wide screening cohort, the use of a handheld ECG 
machine to identify subjects with newly diagnosed AF was cost-effective in the 
general population, as well in subjects ≥65 and ≥75 years old. 
 
Keywords: atrial fibrillation; screening; outcomes; cost-effectiveness analysis.  
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INTRODUCTION 
Atrial fibrillation (AF) is the most incident and prevalent heart rhythm condition1. 
Despite this, AF patients are very frequently asymptomatic, thus exposing patients to 
an increased risk for stroke and major adverse events2,3, with around a quarter of 
patients diagnosed with AF only after the first stroke occurrence4. 
 
In the 2016 European Society of Cardiology (ESC) guidelines, screening procedures 
for AF early detection are recommended opportunistically for subjects ≥65 years 
(Class I, Level of Evidence B)1. Systematic screening is only suggested, with a low 
evidence grade (Class IIb, Level of Evidence B), in very elderly patients (≥75 years) 
or those at high risk of stroke1. 
 
The debate about whether to use opportunistic or systematic screening approaches 
remains controversial. Opportunistic screening is more cost-effective than systematic 
ones5. A large systematic review reported that opportunistic and systematic 
screening programmes reported a similar number of new AF diagnosis6. Several 
studies using population-wide or systematic screening programmes, using handheld 
ECG machines or new technologies-base systems, have reported that these 
programmes are feasible to identify a significant number of new AF cases7–10, as 
well as being also cost-effective in reducing major adverse events, particularly 
reducing stroke and its related healthcare costs9–11. 
 
The aim of this paper was to perform a cost-effectiveness analysis (CEA) and a 
screening performance analysis using a population-wide screening model designed 
after the Belgian Heart Rhythm Week (BHRW) screening programme. 
 
5 
 
METHODS 
Analytic Approach 
Modelling analysis about the use of a population-wide screening programme was 
based on a Markov model [Figure 1] for decision making processes about AF 
detection, clinical management and life-long follow-up. This model has been built 
taking into account the different health states in which the simulated individual can 
be and move between.  
 
The statistical definition of the model is that of a discrete-time discrete-state 
stochastic process with first-order Markov property. This implies that conditionally on 
the current health status for the specific simulated individual, the future status of the 
same individual is independent of previous events. Using a simulation model, we 
analyzed 1000 hypothetical individuals who matched the population of the BHRW 
screening programme7. Simulations have been performed for the overall population 
of adults, as well as for subgroups of subjects ≥65 years and ≥75 years old. The 
model design was computed to account for a screening procedure undertaken yearly 
for 40 consecutive years and simulated the natural dynamics of the cohort 
considered. 
 
The simulation of the natural disease progression and the effect of the screening 
procedure required data including prevalence, incidence, the risk of events, 
morbidity, and mortality. The data, extracted from a Belgian setting, were obtained 
from the BHRW screening programme study7 and additionally supplemented with 
data coming from the available scientific literature. Main parameters used to build the 
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model are reported in Table 1. The simulation has been replicated 10,000 times and 
results are based on average simulated quantities of interest. Sensitivity analyses 
were performed both by assessing the variability of quantities over the simulation 
replicas, and therefore obtaining acceptability curves; and by repeating the study 
after varying input parameters in a grid of reasonable values (not shown).  
 
Study Setting and Use of Handheld ECG 
Study design and main results of the BHRW screening programme have been 
reported7,12. Briefly, the BHRW screening programme is a Belgian 
national campaign on awareness about AF, designed along with an untargeted 
voluntary screening programme organized by the Belgian Hearth Rhythm 
Association (BeHRA) held 1 week a year. Adult subjects have been invited, through 
press conferences and a massive communicational campaign from the main national 
Belgian media, to attend the screening procedure and a clinical questionnaire filled 
independently and anonymously by each subject. From 2010 to 2014 a total of 
82,569 Belgian citizens were screened7. 
 
ECG tracings were collected through a handheld 1-lead ECG machine (Omron, 
HeartScan HCG-801) with a 30-s long recording. Use of this hand-held machine has 
been previously validated as highly accurate to detect the presence of AF, compared 
to a standard 12-leads ECG13. All the procedures were nurse-led. 
 
AF Prevalence and Distribution of Thromboembolic Risk 
According to previously published results, the overall prevalence of AF detected in 
the BHRW screening programme was 1.4%7 and after the exclusion of patients with 
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a previously reported history of AF, a final prevalence of unknown AF was 1.1%. 
Stratifying patients per age subgroups, in patients older than 65 years unknown AF 
was found in 2.0% of patients, while those subjects ≥75 years had a final prevalence 
of 3.1% for detected unknown AF. Prevalence of newly detected AF based on 
occasional pulse check was evaluated according to previously published data14. 
 
In the general cohort of subjects enrolled in BHRW programmed median [IQR] 
CHA2DS2-VASc was 2 [1-3], with 15.5% of subjects with CHA2DS2-VASc 0, 33.5% 
with CHA2DS2-VASc 1 and 51% with CHA2DS2-VASc ≥2. Meanwhile, 86.0% of 
subjects ≥65 years had a CHA2DS2-VASc ≥2.  
 
Risk of Adverse Events and Thromboembolic Risk Treatment 
The primary aim of a screening programme for AF is ultimately to reduce the 
occurrence of thromboembolic events, namely ischemic stroke. AF is an 
independent risk factor for stroke occurrence, increasing up to 5-fold the risk of 
stroke15. Concomitant presence of other risk factors, i.e. age, hypertension, 
congestive heart failure, diabetes mellitus, etc., increases this risk exponentially15. 
Nowadays, thromboembolic risk is routinely evaluated at baseline and is pivotal in 
the clinical decision-making process of prescribing oral anticoagulation (OAC) 
therapy1. Thromboembolic risk stratification is made using a clinical scoring system, 
the CHA2DS2-VASc score16, largely evaluated and validated in several AF cohorts15. 
 
Thromboembolic risk in AF patients untreated with OAC, to compute the model 
presented, was considered as progressively increasing according to CHA2DS2-VASc 
score, as previously reported in ESC 2010 Guidelines17. To simplify the model, 
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patients were considered eligible for OAC prescription for a CHA2DS2-VASc score 
≥2. Death risk for patients without AF were based on epidemiological data about 
general Belgian population and changes in mortality risk due to AF presence, as well 
as relative risk reduction in death rates have been considered according available 
literature18–20. 
 
Recently released ESC guidelines for treatment of AF patients recommended for 
thromboembolic risk reduction, the use of non-vitamin K antagonist oral 
anticoagulants (NOACs) over vitamin K antagonist (VKA), namely warfarin1. 
Considering that no indication exists to preferentially use one NOAC over the others1 
and according to the class-effect in reduction of both thromboembolic and bleeding 
risk that NOACs presented20, to keep the model simple and strictly focused on the 
efficacy of the screening procedure, the model was computed considering that when 
a patient was diagnosed with a new onset AF a generic NOAC was prescribed, 
considering the overall ability in reduction of both thromboembolic and bleeding risk 
demonstrated by all NOACs20. 
 
Resources and Costs 
Handheld ECG machines cost 500 € and could be reused over 5 years (annual cost 
100 €). We considered 2.5 mean devices for each centre, for a total of 90 centres 
throughout Belgium, as reported in the main BHRW paper7. As stated above, all 
screening procedures were nurse-led, with an estimated time of 5 min/test and an 
overall cost of 34.28 € per hour for each nurse. 
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Costs about OAC treatment and associated monitoring, as well as all costs related to 
the occurrence of any stroke or major bleeding, were taken from a Belgian-specific 
setting according to previously published data about modelling analysis in AF in 
Belgium21. Main costs considered in the model are reported in Table 1. 
 
Utility Weights 
To calculate the quality-adjusted life year (QALY), baseline estimates were based on 
a Belgian setting. Discounts in QALYs according AF diagnosis and adverse events 
occurrence were calculated from specific utility weights according previously 
published data for CEA modelling analysis in the Belgian population21. 
 
RESULTS 
Base Case Scenario 
After running the Markov model 10,000 times to generate 1000 simulated subjects 
each time, average results about subjects diagnosed with new AF have been 
reported in Figure 2. We found that the number of patients diagnosed with AF is 
consistently and steadily higher when the population screening procedure is applied, 
in the overall population, in patients ≥65 years old and in patient ≥75 years old. In the 
base-case scenario (Table 2), screening of 1000 subjects from the overall population 
resulted in 106.6 more patients with detected AF. Consequently, 3 fewer strokes 
were obtained with 10 more life years and 5 more QALYs. The number needed-to-
screen (NNS) to avoid 1 stroke was 361 patients screened.  
 
In patients ≥65 years old use of screening procedure identified 80.8 more patients 
with new AF diagnosis, resulting in 3 fewer strokes, 4 more life years and 5 more 
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QALYs. The NNS to avoid 1 stroke was 354. Furthermore, in patients ≥75 years old 
the screening procedure resulted in 71.1 more patients diagnosed with AF, resulting 
in 3 fewer strokes, 13 more life years and 11 more QALYs. The NNS to avoid one 
stroke was 371 screenings performed. 
 
According to Table 2, in the overall population, the incremental cost-effectiveness 
ratio (ICER) for any gained life year was 11,787.8 €, while the ICER for any gained 
QALY was 24,344.5 €. Furthermore, in patients ≥65 years old and ≥75 years old the 
ICER for any gained life year was 19,377.6 € and 17,692.6 €, respectively and the 
ICER for any gained QALY was 5,875.6 € and 6,707.6 €, respectively. 
 
Sensitivity Analyses 
In order to study the uncertainty and variability of all variables considered, a 
probabilistic analysis was performed. The results are reported as acceptability 
curves [Figure 3]. The probabilistic analysis shows that if the willingness to pay for a 
QALY is higher than 4000 €, screening is probably cost-effective for the general 
population, subjects ≥65 years and subjects ≥75 years. 
 
DISCUSSION 
Our modelling cost-effectiveness analysis, in a sample of 1000 hypothetical 
individual, shows that a population screening programme based on a handheld ECG 
machine is effective in identifying a consistently higher number of subjects affected 
with unknown AF, in general population and in both subjects older ≥65 years and 
≥75 years. Identification of an increased number of patients with AF, if properly 
treated with OAC, ultimately lead to a reduction in the number of strokes occurred 
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over subjects’ lifetime. Finally, the implementation of such a screening programme 
results in a clear cost-effective gaining in quality of life in subjects older ≥65 years 
and ≥75 years, while provided a limited advantage when considered among the 
general population, with ICER for gained QALY just barely below 25,000 €. 
 
In the last years, research regarding use of screening strategies to identify patients 
with asymptomatic AF has developed, building up an increasing amount of 
evidence22,23. Two recently published expert consensus from international experts 
and scientific societies strongly support and recommend performing AF screening in 
all subjects ≥65 years, even though it is not suggested as systematic and 
compulsory strategy, but rather than in an opportunistic way22,23. This approach 
matches that suggested by International AF guidelines1 as well as by consensus 
guidance stemming from primary care environment24. Furthermore, use of a 
systematic AF screening is suggested to be considered for subjects ≥75 years22, 
even though guidelines underline how the evidence supporting this type of 
recommendation is scarce (class of recommendation IIb, level of evidence B)1. In 
this context, our data support the use of a population screening in both subjects ≥65 
years and ≥75 years old, providing evidence that such programme will result in a 
significant increase of AF diagnosis and reduction of events, still remaining cost-
effective. Regarding this aspect, we would comment on the evidence that while a 
lower NNS was found for subjects ≥65 years old, compared to the general 
population, in the subjects ≥75 years old we found, contrary on what was expected, 
a slightly higher NNS compared to those ≥65 years old. We can postulate that since 
the risk of AF progressively increases with age, being greater in subjects ≥75 years 
old, the likelihood that AF is diagnosed incidentally would be higher than in younger 
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ones then an increased NNS is needed to avoid the occurrence of a single stroke. 
Another possible explanation could be related to the small proportion of subjects ≥75 
years considered compared to the other age strata, that could have partially 
influenced this aspect. 
 
Recently the US Preventive Services Task Force (USPSTF) released a 
recommendation regarding the use of ECG screening for AF in older (≥65 years) 
adults25. After a systematic revision of current literature26, which concluded that there 
is not enough evidence to establish the balance between benefits and harms of ECG 
screening26, USPSTF did not make any recommendation regarding the use of ECG 
screening, claiming the need for further evidence25. The summary of evidence and 
the subsequent statement are limited by the fact that most of the studies regarding 
screening programmes for AF detection have a cross-sectional design, without any 
active comparator, nor including a follow-up phase to establish if the use of the 
screening programme had an impact on major adverse clinical events.  
 
The present paper supports the concept that using a systematic screening approach 
is able to reduce significantly the occurrence of stroke. In the general population, 
taking as reference the current global population of Belgium, using the screening 
procedure for the all population of Belgium every year will result in more than 34,000 
strokes avoided over the lifetime course, with more than 21,000 strokes avoided in 
the population age ≥65 years old. In this context, recently the results of a 5-year 
observation derived from an AF screening programme, despite not providing 
definitive evidence due to the limited number of subjects, clearly pointed out how 
using a screening programme reduces the occurrence of stroke27 
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Related to the costs expenditure, our paper clearly demonstrates that using this 
population screening programme is cost-effective even in the general population 
when considering the general threshold of 30,000 GBP per QALY22. When limiting 
the screening to the subjects age ≥65 years or those ≥75 years the programme 
appears clearly cost-effective, even though it resulted in a slightly higher cost than 
compared to the few other cost-effectiveness evaluations of AF screening 
activities22. Conversely, compared to a similar paper recently published, evaluating 
the cost-effectiveness of a similar population screening in the Netherlands, our 
programme showed a significantly lower ICER per QALY28. Obviously, the 
implementation of a nationwide general screening population implies a relevant 
impact in terms of commitment and still deserves further evidence to be strongly 
supported. 
 
Limitations 
As per each other modelling analyses, being based on assumptions subjectively 
defined by the authors, this represents an inherited limitation to the study, even 
though the sensitivity analysis clearly showed that our screening programme would 
be cost-effective in most of the cases. Secondly, the analysis is based on a Belgian 
scenario of voluntary subjects attending the screening initiative, that as volunteers 
may also have been more burdened with vague AF-related symptoms and would 
have taken advantage of a free screening procedure; hence, the external validity and 
generalizability of the results presented need to be considered. Furthermore, most 
patients with undetected AF would be found in the first years of the screening 
procedure, but the entire 40-years screening procedure was cost-effective indicating 
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that even a shorter screening programme would be cost-effective. Lastly, we based 
the weights related to NOACs derived from randomized clinical trials and the patients 
included in the trials are likely to differ from the overall real-life population. 
 
CONCLUSIONS 
The use of a handheld ECG machine in a population screening programme is cost-
effective in identifying new AF patients and reducing stroke occurrence in the 
general population, subjects ≥65 and subjects ≥75 years. Our results clearly support 
the use of more systematic screening for AF in patients ≥65 and ≥75 years old. 
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FIGURE LEGENDS 
 
Figure 1: Basic description of Markov Model used for this analysis.  
Legend: Part 1 refers to the screening procedure. Part 2 refers to treatment and 
follow-up following the screening phase. Squares indicate clinical choices made by 
physicians. Circles indicates the clinical events that may occur probabilistically. 
 
Figure 2: Number of patients found in AF among the 1000 subjects simulated 
in the model.  
Legend: Red line indicates no screening procedure performed. Black line indicates 
screening procedure performed. 
 
Figure 3: Acceptability Curves for Sensitivity analysis. 
  
 
21 
Table 1: Relevant Parameters in the Model 
Parameter Value Reference 
Age Classes Distribution (%) 
<65 years 
65-74 years 
≥75 years 
 
69.5% 
21.8% 
8.6% 
7 
Gender Distribution (%) 
Male 
Female 
 
41.4% 
58.6% 
7 
Unknown AF Prevalence (%) 
General Population 
Subjects ≥65 years 
Subjects ≥75 years 
 
1.1% 
2.0% 
3.1% 
7 
CHA2DS2-VASc Distribution (%) 
CHA2DS2-VASc 0 
CHA2DS2-VASc 1 
CHA2DS2-VASc 2 
CHA2DS2-VASc 3 
CHA2DS2-VASc ≥4 
 
15.5% 
33.5% 
18.6% 
9.4% 
23.0% 
7 
Stroke Risk for Untreated AF (%/year) 
CHA2DS2-VASc 0 
CHA2DS2-VASc 1 
CHA2DS2-VASc 2 
CHA2DS2-VASc 3 
CHA2DS2-VASc 4 
CHA2DS2-VASc 5 
CHA2DS2-VASc 6 
CHA2DS2-VASc 7 
CHA2DS2-VASc 8 
CHA2DS2-VASc 9 
 
0% 
1.3% 
2.2% 
3.2% 
4.0% 
6.7% 
9.8% 
9.6% 
6.7% 
15.2% 
17 
Stroke Risk Difference with VKAs (RRR) -64% 18 
Stroke Risk Difference with NOACs (RRR) -19% 20 
Major Bleeding Risk Difference with VKAs (RRR) +66% 18 
Major Bleeding Risk Difference with NOACs (RRR) -14% 20 
Death Risk Difference with VKAs (RRR) -26% 18 
 
22 
Death Risk Difference with NOACs (RRR) -10% 20 
Utility Weight AF 0.73 21 
Utility Weight Stroke 0.56 21 
Utility Weight Major Bleeding 0.15 21 
Main Costs (Mean) 
ECG Handheld (€ per device/year) 
Screening Associated Costs (€ per hour) 
NOAC Cost (€ per day) 
NOAC Routine Care Cost (€ per year) 
 
100 € 
34.28 € 
3.50 € 
91 € 
 
a 
a 
21 
21 
Legend: a= previously unpublished data from BHRW programme; AF= atrial 
fibrillation; NOAC= non-vitamin K antagonist oral anticoagulant; VKAs= vitamin K 
antagonists; RRR= relative risk reduction.
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Table 2: Base-case scenario for 1000 screened individuals 
 Lifetime 
Costs 
Strokes Life 
Years 
QALY ICER per gained  
life year 
ICER per gained  
QALY 
General Population       
No Screening 178,086.5 € 11.1 19,139.1 19,081.4   
Screening 290,071.0 € 8.3 19,148.6 19,086.0 11,787.8 € 24,344.5 € 
Subjects ≥65 years       
No Screening 175,301.2 € 10.9 10469.7 9,982.7   
Screening 256,687.2 € 8.0 10473.9 9,987.3 19,377.6 € 17,692.6 € 
Subjects ≥75 years       
No Screening 163,528.2 € 10.1 8,886.5 8,817.9   
Screening 239,323.8 € 7.4 8,899.4 8,829.2 5,875.6 € 6,707.6 € 
Legend: ICER= incremental cost-effectiveness ratio; QALY= quality adjusted life year.  
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